Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Qilu Pharmaceutical

Tracked across 5 events · 30 articles · First seen Jul 13, 2026 · Last active Sep 10, 2026

Sentiment
13
Attention
4
Events
5
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 20
Business
Impact: Qilu is the developer and supplier of QL2107, leveraging its R&D and manufacturing strengths to gain US market access through Cipla.
Sep 03, 2026 · 6 articles
2 40
Business
Impact: Collaboration partner; contributes to Insilico's revenue growth, but no direct impact from index inclusion.
Jul 20, 2026 · 6 articles
3 0
Business
Impact: Qilu Pharmaceutical is mentioned as a prior collaborator with Insilico, but is not directly involved in this event.
Jul 13, 2026 · 6 articles
4 0
Regulatory
Impact: Qilu Pharmaceutical is a strategic partner of ArkBio, potentially involved in manufacturing or commercialization in China.
Jul 20, 2026 · 6 articles
4 5
Tech
Insilico Medicine announced on September 9-10, 2026 that it has dosed the first patient with Rentosertib (ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase III clinical trial for idiopathic pulmonary fibrosis (IPF), at United Medical College…
Impact: Qilu Pharmaceutical is mentioned as a partner in Insilico's collaborations. The event has minimal direct impact on Qilu Pharmaceutical.
Sep 10, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Qilu Pharmaceutical live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.